
Joint statement by the leading patient group WFIPP and MUVON Therapeutics AG
Today, the World Federation of Incontinence and Pelvic Problems (WFIPP) released a statement of partnership and collaboration with...
Joint statement by the leading patient group WFIPP and MUVON Therapeutics AG
MUVON Therapeutics is supported by the Lichtsteiner Foundation
MUVON's CEO Deana Mohr featured in Top 30 In Vivo's Rising Leaders 2022
CEO Deana Mohr presented MUVON in interview for BioInnovation Spotlight
Translation and automation hurdles for cell therapies
MUVON wins second place at IFAS Innovation Challenge 2021
Deana Mohr wins spot in Venture Leaders Medtech 2021
MUVON featured by Startupticker
MUVON Therapeutics selected as finalist for the 2021 >>venture>> Startup Competition
MUVON Therapeutics selected for Tech4Eva accelerator program
Greater Zurich Area features MUVON Therapeutics in article on successful biotech innovations
MUVON is being accelerated by Wyss Zurich
Modern Therapy of Urinary Incontinence Using Muscle Stem Cells (Article in German)
The Beginning of the MUVON Story
Muscle Precursor Cells for the Restoration of Irreversibly Damaged Sphincter Function
The role of donor age and gender in the success of human muscle precursor cell transplantation